Search Results - philip+reigan

5 Results

Sort By:

WEE1 Kinase Inhibitors for the Treatment of Glioblastoma

Wee1 kinase participates in the G2-M checkpoint to prevent mitosis in the presence of DNA damage and therefore may play an important role in drug resistance to DNA alkylating agents, by allowing tumor cells to repair DNA damage prior to mitosis. Inhibition of the Wee1 kinase is known to potentiate the effect of chemotherapy in a variety of tumor...

Published: 11/30/2023 | Inventor(s): Philip Reigan, Christopher Matheson

Disease Areas Oncology

Category(s): Therapeutics

Inhibitors of Wee1 kinase for pediatric and adult cancers

The Wee1 kinase participates in the G2-M checkpoint to prevent mitosis in the presence of DNA damage and therefore may play an important role in drug resistance to DNA alkylating agents, by allowing tumor cells to repair DNA damage prior to mitosis. Inhibition of the Wee1 kinase is known to potentiate the effect of chemotherapy in a variety of tumor...

Published: 11/30/2023 | Inventor(s): Philip Reigan, Donald Backos, Christopher Matheson, Kimberly Casalvieri

Disease Areas Oncology

Category(s): Therapeutics

Small Molecule Inhibitors of STAT3 for the Treatment of AML

Signal transducer and activator of transcription-3 (STAT3) is involved in multiple cancer types and inflammatory diseases. STAT3 is particularly important in leukemic stem cell proliferation and AML progression, which makes it an attractive target for therapeutic inhibition. A team of investigators at the University of Colorado led by Dr. Reigan...

Published: 11/30/2023 | Inventor(s): Philip Reigan, Donald Backos, Christopher Matheson, Steffanie Furtek

Disease Areas Oncology

Category(s): Therapeutics

Oxindol-3-ylidene inhibitors of AMP-activated protein kinase (AMPK)

The oral tyrosine kinase inhibitor sunitinib, used in the clinic to treat advanced renal cell carcinoma and gastrointestinal stromal tumors, is a potent AMPK inhibitor. However, sunitinib has been associated with clinical cardiac toxicity through non-specific binding to the AMPKα2 isoform. Dr. Philip Reigan and a team of researchers have revealed...

Published: 11/30/2023 | Inventor(s): Philip Reigan, Donald Backos, Christopher Matheson, Craig Jordan

Disease Areas Oncology

Category(s): Therapeutics

Development of AMPK PROTAC degraders and their hypoxia-activated prodrugs

Dr. Philip Reigan and a team of researchers are developing novel oxindole-based inhibitors of 5' AMP-activated protein kinase (AMPK), a kinase with a critical function in metabolic regulation. An extension of developing AMPK inhibitors is to couple these inhibitors to a the cereblon (CRBN)-binding ligand, pomalidomide, as a PROteolysis TArgeting...

Published: 5/9/2023 | Inventor(s): Philip Reigan

Disease Areas Oncology

Category(s): Therapeutics